SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Emerg Microbes Infect. 2020 Dec;9(1):2091-2093. doi: 10.1080/22221751.2020.1823890.

Abstract

We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.

Keywords: SARS-CoV-2; antibody; neutralization; non-severe; severe.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Neutralizing / blood*
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology
  • Betacoronavirus / immunology*
  • COVID-19
  • Coronavirus Infections / immunology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neutralization Tests
  • Nucleocapsid / immunology*
  • Pandemics
  • Pneumonia, Viral / immunology
  • SARS-CoV-2
  • Severity of Illness Index
  • Spike Glycoprotein, Coronavirus / immunology*
  • Viral Envelope Proteins / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antigens, Viral
  • Spike Glycoprotein, Coronavirus
  • Viral Envelope Proteins

Grant support

This work was supported by The JBP Foundation; the Wu Family China Center; and Jack Ma Foundation. For the research reported in this publication, LP was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number T32AI114398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.